

Clinical Trial Protocol

Iranian Registry of Clinical Trials

10 Jun 2026

The efficacy of *Plantago major* syrup on severity of cough in acute bronchitis

Protocol summary

Study aim

investigating the therapeutic effect of *Plantago major* on the severity of cough in acute bronchitis

Design

randomized Placebo-controlled clinical trial (Phase 3), in 80 patients with a clinical diagnosis of acute bronchitis. Randomization is done using permuted block randomization. The drugs are studied by Sanabel Daru Co. in two categories (drugs and placebo) and coded by a statistician and placed in blocks of 4 (containing 2 from each group). And given blindly to the researcher. Patients are placed in one of the *Plantago major* syrup or Placebo groups for 10 days.

Settings and conduct

80 patients with symptoms of acute bronchitis who are referred to the Infectious Diseases Clinic of Ayatollah Rouhani Hospital in Babol evaluate with the BSS (Bronchitis Severity Scale) questionnaire. After assessing the inclusion and exclusion criteria, patients are randomly assigned to one of the *Plantago major* syrup or Placebo groups and will be evaluated in 5 and 10 days of consuming the medications.

Participants/Inclusion and exclusion criteria

Inclusion criteria: 20-75 years old; BSS equal to or greater than 5 on the first visit; Symptoms begin less than two weeks before the study begins Exclusion criteria: Pregnant or lactating women; Patients who received specific medications within 4 weeks of study; Patients who have taken a cough and sputum medication for the week before the study or have a history of a specific illness.

Intervention groups

Intervention: *plantago major* and placebo 10 ccs in three times, for 10 days

Main outcome variables

Bronchitis Severity Scale, the severity of cough, quality of life in acute cough (Leicester Cough Questionnaire)

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20200105046009N2**

Registration date: **2020-07-12, 1399/04/22**

Registration timing: **prospective**

Last update: **2020-07-12, 1399/04/22**

Update count: **0**

Registration date

2020-07-12, 1399/04/22

Registrant information

Name

Seyyed Ali Mozaffarpur

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 11 3219 4728

Email address

dr.mozaffarpur@mubabol.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2020-08-05, 1399/05/15

Expected recruitment end date

2021-01-18, 1399/10/29

Actual recruitment start date

2020-08-05, 1399/05/15

Actual recruitment end date

2021-03-19, 1399/12/29

Trial completion date

2021-04-20, 1400/01/31

Scientific title

The efficacy of Plantago major syrup on severity of cough in acute bronchitis

Public title

effect of plantago major on severity of cough

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria:

age between 20 to 75 years old acute cough clinical diagnosis of acute bronchitis

Exclusion criteria:

Pregnant or lactating women Patients who took a cough and sputum medication for one week before the study History of respiratory disease such as chronic bronchitis, bronchiectasis, asthma-pneumonia, cystic fibrosis, lung cancers or active pulmonary tuberculosis Kidney or liver failure Genetic diseases such as galactose intolerance or lactose intolerance History or presence of cardiovascular disease, neurological disease, metabolic disease or mental disorders. Hematologic disease or malignant tumor (unless recurrent within 5 years) A history of alcohol or substance abuse

Age

From **20 years** old to **75 years** old

Gender

Both

Phase

3

Groups that have been masked

- Participant
- Care provider
- Investigator
- Outcome assessor
- Data analyser
- Data and Safety Monitoring Board

Sample size

Target sample size: **80**

More than 1 sample in each individual

Number of samples in each individual: **40**

Based on similar studies to indicate a 25% difference in cough remission, the sample size was calculated to be 36% for each group, taking into account the first type error of 5% and the power of 90%. Considering the possibility of a 10% drop, the final sample size in each group was 40 individuals. (Total 80 people)

Actual sample size reached: **36**

Randomization (investigator's opinion)

Randomized

Randomization description

Drugs in two categories (drug and placebo) are made by Sanabel Daru Co. and sent to the statistician.

Randomization is done using permuted blocks randomization. The size of the blocks is considered 4. All possible combinations are determined from a sequence of 4 of the two drugs (6 combinations), and then their sequence is determined using a table of random numbers. The statistician encodes them and gives them to the researcher blind. Unlock codes will be done after the end of the study. In case of side effects, the drug code will be unlocked.

Blinding (investigator's opinion)

Double blinded

Blinding description

Placebo syrup and medicine will be prepared in the same form, label, taste, and odor, by the Sanabel DaruCo. The only one who knows the identity of the syrups is the biostatistician of the study.

Placebo

Used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics committee of Babol University of Medical Sciences

Street address

Babol, Sargor Ghasemi avenue, Babol University of Medical science

City

Babol

Province

Mazandaran

Postal code

4718647745

Approval date

2020-01-19, 1398/10/29

Ethics committee reference number

IR.MUBABOL.HRI.REC.1398.342

Health conditions studied

1

Description of health condition studied

Brunchit

ICD-10 code

J21

ICD-10 code description

Acute bronchiolitis

Primary outcomes

1

Description

severity of acute bronchitis

Timepoint

Assessing patients at the first visit (before starting the study), on the fifth day and on the tenth day after starting treatment

Method of measurement

Bronchitis Severity Score (BSS) questionnaire

Secondary outcomes

1

Description

quality of life for acute cough

Timepoint

Before starting treatment, after the end of treatment

Method of measurement

Standard Quality of Life Questionnaire for Acute Cough (Leicester Cough Questionnaire)

2

Description

severity of cough

Timepoint

Assessing patients at the first visit (before starting the study), on the fifth day and on the tenth day after starting treatment

Method of measurement

cough evaluating questionnaire based on Visual Analog Scales

Intervention groups

1

Description

Intervention group: Plantago major syrup containing extract of the seed of Plantago major, made by Sanabel Daru Company is used. Syrups are given to the patient on a weekly basis in 300 cc pets. The patient takes 30 ccs orally (10 ccs three times every 8 hours) daily for 10 days.

Category

Treatment - Drugs

2

Description

Control group: Placebo syrups with the same taste, color, smell, shape and label of the Plantago major syrup will be made by Sanabel Daru Company. Syrups are given to the patient on a weekly basis in 300 cc pets. The patient takes 30 cc orally (10 cc in three times, every 8 hours) daily for 10 days.

Category

Placebo

Recruitment centers

1

Recruitment center

Name of recruitment center

Roohani Hospital

Full name of responsible person

Seyyed Ali Mozaffarpur

Street address

Babol, Ganjafrooz Ave, Near Babol University of Medical Science. Roohani Hospital

City

Babol

Province

Mazandaran

Postal code

4717647745

Phone

+98 11 3219 4728

Fax

+98 11 3219 4730

Email

Seyyedali1357@gmail.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Babol University of Medical Sciences

Full name of responsible person

Reza Ghadimi

Street address

Babol, Sargord Ghasemi Ave, Babol University of Medical Science

City

Babol

Province

Mazandaran

Postal code

4717647745

Phone

+98 11 3219 4728

Email

seyyedali1357@gmail.com

Grant name

Babol university of medical sciences

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Babol University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Babol University of Medical Sciences

Full name of responsible person

Seyyed Ali Mozaffarpur

Position

Associate professor

Latest degree

Ph.D.

Other areas of specialty/work

Traditional Medicine

Street address

Babol. Ganj afrooz. Babol university of Medical Science. School of Persian Medicine

City

Babol

Province

Mazandaran

Postal code

4718647745

Phone

+98 11 3219 4728

Fax

+98 11 3219 4730

Email

seyyedali1357@gmail.com

Person responsible for scientific inquiries

Contact**Name of organization / entity**

Babol University of Medical Sciences

Full name of responsible person

Seyyed Ali Mozaffarpur

Position

Associate professor

Latest degree

Ph.D.

Other areas of specialty/work

Traditional Medicine

Street address

Ganjafrooz st., Babol university of Medical Science

City

Babol

Province

Mazandaran

Postal code

4718647745

Phone

+98 11 3219 4728

Fax

+98 11 3219 4730

Email

seyyedali1357@gmail.com

Person responsible for updating data

Contact**Name of organization / entity**

Babol University of Medical Sciences

Full name of responsible person

seyyed Ali Mozaffarpur

Position

Associate professor

Latest degree

Ph.D.

Other areas of specialty/work

Traditional Medicine

Street address

Ganj afrooz st., Babol university of medical science

City

Babol

Province

Mazandaran

Postal code

4717647745

Phone

+98 11 3219 4728

Fax

+98 11 3219 4730

Email

seyyedali1357@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

Yes - There is a plan to make this available

Statistical Analysis Plan

Yes - There is a plan to make this available

Informed Consent Form

Yes - There is a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available

Title and more details about the data/document

the primary outcome measure

When the data will become available and for how long

starting after publication

To whom data/document is available

people working in academic institutions

Under which criteria data/document could be used

systematic review or meta-analysis

From where data/document is obtainable

email to seyyedali1357@gmail.com

What processes are involved for a request to access data/document

email to seyyedali1357@gmail.com

Comments